Michael Narachi

This profile gathers the share dealings of Michael Narachi across 2 companies, led by Ultragenyx Pharmaceutical Inc. and Orexigen Therapeutics, Inc. The record holds 9 filings, for trades running from 29 May 2015 to 15 May 2025.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

Most recently, on 19 May 2025, the filings show a share grant in Ultragenyx Pharmaceutical Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.